Zhaoke Ophthalmology Limited has announced that it has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL™ PF in Indonesia. Under the agreement, PT Ferron is granted exclusive rights to import, promote, distribute, market, and sell BRIMOCHOL™ PF, an innovative drug for the treatment of presbyopia, in Indonesia. Zhaoke Ophthalmology will receive an upfront payment and is eligible for additional milestone payments based on specific achievements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.